| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/11/2025 | $85.00 → $100.00 | Neutral → Buy | Goldman |
| 1/8/2025 | $95.00 → $103.00 | Hold → Buy | Jefferies |
| 9/26/2024 | $84.00 → $74.00 | Neutral → Sell | UBS |
| 9/18/2024 | $100.00 | Neutral → Buy | BTIG Research |
| 9/9/2024 | $90.00 | Neutral | JP Morgan |
| 8/6/2024 | $100.00 | Buy | Stifel |
| 5/30/2024 | $87.00 | Neutral | Goldman |
| 2/15/2024 | $100.00 | Buy | HSBC Securities |
| 2/12/2024 | $66.00 → $88.00 | Sell → Neutral | UBS |
| 11/30/2023 | $80.00 | Hold | Jefferies |
A new cloud-suite of enterprise imaging solutions, the Genesis portfolio, is designed to help improve patient care coordination, reduce operational costs, and maintain robust security standards Allows healthcare providers to more easily store, access, and manage large volumes of medical images from anywhere, anytime Demonstrates GE HealthCare's commitment to increasing the number of cloud-enabled product offerings by 2028, generating recurring revenue through cloud adoption and SaaS-based models, and leading the digital transformation GE HealthCare (NASDAQ:GEHC) today announced its new Genesis solutions, a portfolio of cloud enterprise imaging software-as-a-service (SaaS) solution
Yihao Zhang to retire from GE HealthCare, hands over leadership position to long-time Johnson & Johnson executive, Will Song, a highly knowledgeable and respected leader with a proven track record and decades of industry experience GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, today announced that Yihao Zhang, president and CEO, China, will retire from the company effective July 1, 2025. Will Song, a Johnson & Johnson veteran for over 20 years, has been named GE HealthCare's new president and CEO, China, and will join the company on April 1, 2025, ahead of leading the region starting July 1 following Yihao's departure. Yihao's planned retirement allowed GE
Freelium, a helium-freei sealed magnet platform in development, aims to dramatically reduce liquid helium usage without sacrificing power efficiency, operational security and clinical performance Leveraging GE HealthCare's proven lightweight, intelligent magnet technology, Freelium will be optimized to seamlessly integrate with future technological advancements and upgrade options, offering flexibility and reliability for imaging departments GE HealthCare (NASDAQ:GEHC) today unveiled Freelium™,ii a next-generation sealed magnet platform, that aims to enable high-quality Magnetic Resonance (MR) imaging with less than 1% of helium used in conventional magnet technology to help support
The first patient doses of GE HealthCare's new FDA-approved PET radiotracer, Flyrcado™ (flurpiridaz F 18) injection, are being administered at early adopter sites around the United States. First-of-its-kind radiopharmaceutical, Flyrcado, a PET myocardial perfusion imaging (MPI) agent, delivers higher diagnostic efficacy in patients with known or suspected coronary artery disease (CAD), compared to SPECT MPI, the predominant procedure used in nuclear cardiology today. Available as a ready-to-use unit dose, Flyrcado can expand clinician and patient access to PET MPI and is expected to be available to nearly all of the existing cardiac PET centers in the US by the end of 2025. GE Hea
Fourth Quarter 2024 Revenue growth was 2% year-over-year; Organic revenue growth* was 2% Net income margin was 13.5% versus 7.7% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 18.7% versus 16.1% Diluted earnings per share (EPS) were $1.57 versus $0.88 for the prior year; Adjusted EPS* was $1.45 versus $1.18 Cash flow from operating activities was $913 million versus $1.1 billion for the prior year; Free cash flow* was $811 million versus $956 million Full Year 2024 Revenue growth was 1% year-over-year; Organic revenue growth* was 1% Net income margin was 10.1% versus 8.0% for the prior year; Adjusted EBIT margin* was 16.3% versus 15.1
USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, Feb. 11, 2025 /PRNewswire/ -- USA News Group News Commentary – Weeks after the monumental $500-billion announcement of Project Stargate, which includes aims to transform healthcare, a growing number of health executives are seeing the promise of Artificial Intelligence (AI) in their industry. A recent poll from Deloitte found that 40% of health execs say generative AI (genAI) pays off for their businesses. Early in 2025, it's becoming clearer that genAI is revolutionizing diagnostics, enhancing treatment options, and personalizing patient care. Beyond Stargate's big players, a growing number of innovator
GE HealthCare (NASDAQ:GEHC) is announcing that members of its management team will present at Citi's 2025 Medtech and Life Sciences Access Day on February 27, 2025 at 2:15pm CT / 3:15 pm ET. A webcast of this event can be accessed at the GE HealthCare website: https://investor.gehealthcare.com/news-events/events on the date and time listed above. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happi
New $138 million facility at GE HealthCare's Cork manufacturing site will enable 25 million more patient doses of contrast media per year by the end of 2027i Demand for CT and X-Ray contrast media, used to enhance medical imaging procedures globally, is estimated to double in the next ten yearsii Investment will create additional capacity to cater for growing demand, while offering increased flexibility and resiliency for security of supply GE HealthCare (NASDAQ:GEHC) today announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A new state-of-the-art facility on the grounds of the existing site will enable
This is GE HealthCare's first appearance on the list, marking a significant milestone as an independent company GE HealthCare (NASDAQ:GEHC) has been named to 2025 Fortune World's Most Admired Companies™ list. The company has been recognized across several categories including the quality of management, products and services, innovation, value as a long-term investment, financial soundness, talent acquisition and retention, community and environmental responsibility, global business, and use of corporate assets. Being named to Fortune World's Most Admired Companies™ list for the first time, two years after becoming an independent company, is a testament to GE HealthCare's progress agai
Latest Voluson Expert 22, 20 and 18 ultrasound systems harness artificial intelligence and advanced tools and software for more efficient assessments Voluson Expert Series delivers elevated performance, with focus on first trimester to reveal clearer anatomical details, aiding earlier detection and boosting diagnostic confidence GE HealthCare (NASDAQ:GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the updated portfolio of Voluson™ Expert Series ultrasound systems. Voluson Expert 22, 20 and 18 combine high resolution image quality with advanced ultrasound technology and an ergonomic design for efficient workflow and
Fourth Quarter 2024 Revenue growth was 2% year-over-year; Organic revenue growth* was 2% Net income margin was 13.5% versus 7.7% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 18.7% versus 16.1% Diluted earnings per share (EPS) were $1.57 versus $0.88 for the prior year; Adjusted EPS* was $1.45 versus $1.18 Cash flow from operating activities was $913 million versus $1.1 billion for the prior year; Free cash flow* was $811 million versus $956 million Full Year 2024 Revenue growth was 1% year-over-year; Organic revenue growth* was 1% Net income margin was 10.1% versus 8.0% for the prior year; Adjusted EBIT margin* was 16.3% versus 15.1
GE HealthCare (NASDAQ:GEHC) will announce its fourth quarter and full year 2024 financial results before the market opens on Thursday, February 13, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digit
Company updates medium-term framework with progress toward financial goals; increases quarterly cash dividend by approximately 17% GE HealthCare (NASDAQ:GEHC) will host its Investor Day today at Nasdaq MarketSite in New York, NY. The event begins at 8:00 am ET / 7:00 am CT and can be viewed virtually here. Registration is required for in-person attendance. The event will feature presentations from GE HealthCare President and CEO Peter Arduini, GE HealthCare Vice President and CFO Jay Saccaro, and other members of the management team, who will discuss the company's vision and precision care strategy, progress since its spin-off from General Electric Company in 2023, and key growth areas.
Revenue growth was 1% year-over-year; Organic revenue growth* was 1% Net income margin was 9.7% versus 7.8% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 16.3% versus 15.4% Diluted earnings per share (EPS) were $1.02 versus $0.83 for the prior year; Adjusted EPS* was $1.14 versus $0.99 Cash flow from operating activities was $742 million versus $650 million for the prior year; Free cash flow* was $651 million versus $570 million Company raises low end of full-year 2024 Adjusted EBIT margin* and Adjusted EPS* guidance with continued execution; trending toward the lower end of Organic revenue growth* range GE HealthCare (NASDAQ:GEHC) today repor
GE HealthCare (NASDAQ:GEHC) will announce its third quarter 2024 financial results before the market opens on Wednesday, October 30, 2024. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions inno
The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.03 per share of Common Stock for the third quarter of 2024 payable on November 15, 2024 to all shareholders of record as of October 18, 2024. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, c
Revenues were flat year-over-year; Organic revenue growth* was 1% Net income margin was 8.9% versus 8.7% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 15.3% versus 14.8% Diluted earnings per share (EPS) were $0.93 versus $0.91 for the prior year; Adjusted EPS* was $1.00 versus $0.92 Cash flow from operating activities was $(119) million versus $(67) million for the prior year; Free cash flow* was $(182) million versus $(136) million Company updates full-year guidance for Organic revenue growth* and Adjusted EBIT margin* GE HealthCare (NASDAQ:GEHC) today reported financial results for the second quarter ended June 30, 2024. GE HealthCare
GE HealthCare (NASDAQ:GEHC), a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, will announce its second quarter 2024 financial results before the market opens on Wednesday, July 31, 2024. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global
The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.03 per share of Common Stock for the second quarter of 2024 payable on August 15, 2024 to all shareholders of record as of July 19, 2024. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, con
Revenues declined 1% year-over-year; Organic revenue growth* was approximately flat Net income margin was 8.0% versus 7.9% for the prior year; Adjusted Earnings Before Interest and Taxes (EBIT) margin* was 14.7% versus 14.1% Diluted earnings per share (EPS) were $0.81 versus $0.41 for the prior year; Adjusted EPS* was $0.90 versus $0.85 Cash flow from operating activities was $419 million versus $468 million for the prior year; Free cash flow* was $274 million versus $325 million; repaid $150 million of debt in January 2024 Reaffirming full year 2024 guidance GE HealthCare (NASDAQ:GEHC), a leading global precision care innovator, today reported financial results for the firs
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
Collaboration has always been important in the healthcare industry, but in this era of digital health, teamwork across institutions has become essential Enhancing Elekta's radiation therapy offerings with GE HealthCare's MIM Software medical imaging management solutions will help drive greater benefits for global healthcare systems This new collaboration complements GE HealthCare and Elekta's existing global commercial collaboration agreement, which enables the two companies to provide hospitals and cancer patients a comprehensive radiation therapy offering across imaging and treatment Weeks after closing its acquisition of MIM Software – a global provider of medical imaging analy
Goldman upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00 from $85.00 previously
Jefferies upgraded GE HealthCare from Hold to Buy and set a new price target of $103.00 from $95.00 previously
UBS downgraded GE HealthCare from Neutral to Sell and set a new price target of $74.00 from $84.00 previously
BTIG Research upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00
JP Morgan initiated coverage of GE HealthCare with a rating of Neutral and set a new price target of $90.00
Stifel initiated coverage of GE HealthCare with a rating of Buy and set a new price target of $100.00
Goldman initiated coverage of GE HealthCare with a rating of Neutral and set a new price target of $87.00
HSBC Securities initiated coverage of GE HealthCare with a rating of Buy and set a new price target of $100.00
UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $88.00 from $66.00 previously
Jefferies initiated coverage of GE HealthCare with a rating of Hold and set a new price target of $80.00
10-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
424B3 - GE HealthCare Technologies Inc. (0001932393) (Filer)
FWP - GE HealthCare Technologies Inc. (0001932393) (Subject)
8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)
10-Q - GE HealthCare Technologies Inc. (0001932393) (Filer)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)